Clinical Trial Update: Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4 [Phase 1]

View source ↗

Summary

Phase 1 study to determine whether a single dose of olokizumab alters the pharmacokinetics of cytochrome P450 substrates (CYP1A2, CYP2C9, CYP2C19, CYP3A4) in su…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Olokizumab (olokizumab)

Snippet

Sponsor: R-Pharm International, LLC | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED | Results posted: 2024-08-15